Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review

Weide Rudolf, Koppler Hubert, Antras Lucia, Smith Michael, Eva Chang MPH, Green Jesse, Wintfeld Neil, Neary Maureen P, Duh Mei Sheng

Year : 2010| Volume: 6| Issue : 1 | Page no: 31-35

   This article has been cited by
 
1 Myeloma-related Kidney Disease
Nelson Leung,Samih H. Nasr
Advances in Chronic Kidney Disease. 2014; 21(1): 36
[Pubmed]  [Google Scholar] [DOI]
2 Osteoporosis treatment: why ibandronic acid?
Maurizio Rossini,Giovanni Orsolini,Silvano Adami,Vidya Kunnathully,Davide Gatti
Expert Opinion on Pharmacotherapy. 2013; 14(10): 1371
[Pubmed]  [Google Scholar] [DOI]
3 Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer
Kent Søe,Jean-Marie Delaissé,Erik H. Jakobsen,Charlotte T. Hansen,Torben Plesner
Acta Oncologica. 2013; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Zalecenia Polskiej Grupy Szpiczakowej dotyczace rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013
Anna Dmoszynska,Adam Walter-Croneck,Lidia Usnarska-Zubkiewicz,Beata Stella-Holowiecka,Jan Walewski,Grzegorz Charlinski,Wieslaw Wiktor Jedrzejczak,Elzbieta Wiater,Ewa Lech-Maranda,Joanna Manko,Dominik Dytfeld,Mieczyslaw Komarnicki,Krzysztof Jamroziak,Tadeusz Robak,Artur Jurczyszyn,Aleksander Skotnicki,Krzysztof Giannopoulos
Acta Haematologica Polonica. 2013; 44(1): 3
[Pubmed]  [Google Scholar] [DOI]
5 Osteoporosis treatment: Why ibandronic acid?
Rossini, M. and Orsolini, G. and Adami, S. and Kunnathully, V. and Gatti, D.
Expert Opinion on Pharmacotherapy. 2013; 14(10): 1371-1381
[Pubmed]  [Google Scholar]
6 Guidelines of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2013 [Zalecenia PolskiejGrupy Szpiczakowejdotycza̧ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013]
Dmoszyńska, A. and Walter-Croneck, A. and Usnarska-Zubkiewicz, L. and Stella-Hołowiecka, B. and Walewski, J. and Charliński, G. and Jȩdrzejczak, W.W. and Wiater, E. and Lech-Marańda, E. and Mańko, J. and Dytfeld, D. and Komarnicki, M. and Jamroziak, K. and Robak, T. and Jurczyszyn, A. and Skotnicki, A. and Giannopoulos, K.
Acta Haematologica Polonica. 2013; 44(1): 3-47
[Pubmed]  [Google Scholar]
7 Renal function in IV bisphosphonate therapy in common practice [Renální funkce při i.v. terapii bisfosfonáty v běžné praxi osteocentra]
Bubeníček, P. and Kasalický, P. and Rosa, J.
Osteologicky Bulletin. 2012; 17(3): 84-89
[Pubmed]  [Google Scholar]
8 Renal complications from bisphosphonate treatment
Hirschberg, R.
Current Opinion in Supportive and Palliative Care. 2012; 6(3): 342-347
[Pubmed]  [Google Scholar]
9 Current Approach to Diagnosis and Management of Acute Renal Failure in Myeloma Patients
Leung, N. and Behrens, J.
Advances in Chronic Kidney Disease. 2012; 19(5): 297-302
[Pubmed]  [Google Scholar]
10 Denosumab for treatment of breast cancer bone metastases and beyond
Julie R Nangia,Joseph D Ma,Christine M Nguyen,Margaret AS Mendes,Meghana V Trivedi
Expert Opinion on Biological Therapy. 2012; 12(4): 491
[Pubmed]  [Google Scholar] [DOI]
11 Therapeutic approaches to myeloma bone disease: An evolving story
Vito Longo,Oronzo Brunetti,Stella D’Oronzo,Franco Dammacco,Franco Silvestris
Cancer Treatment Reviews. 2012; 38(6): 787
[Pubmed]  [Google Scholar] [DOI]
12 Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma
Gerrard Teoh,Yuming Chen,Kihyun Kim,Alok Srivastava,Vasant R. Pai,Sung-Soo Yoon,Cheolwon Suh,Yeo-Kyeoung Kim
Clinical Lymphoma Myeloma and Leukemia. 2012; 12(2): 118
[Pubmed]  [Google Scholar] [DOI]
13 Renal complications from bisphosphonate treatment
Raimund Hirschberg
Current Opinion in Supportive and Palliative Care. 2012; 6(3): 342
[Pubmed]  [Google Scholar] [DOI]
14 Current Approach to Diagnosis and Management of Acute Renal Failure in Myeloma Patients
Nelson Leung,Judith Behrens
Advances in Chronic Kidney Disease. 2012; 19(5): 297
[Pubmed]  [Google Scholar] [DOI]
15 Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: A retrospective analysis
Fidan, E., Yildiz, B., Kavgaci, H., Ozdemir, F., Aydin, F.
Wspolczesna Onkologia. 2012; 16(2): 176-178
[Pubmed]  [Google Scholar]
16 Denosumab for treatment of breast cancer bone metastases and beyond
Nangia, J.R., Ma, J.D., Nguyen, C.M., Mendes, M.A.S., Trivedi, M.V.
Expert Opinion on Biological Therapy. 2012; 12(4): 491-501
[Pubmed]  [Google Scholar]
17 Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma
Teoh, G., Chen, Y., Kim, K., Srivastava, A., Pai, V.R., Yoon, S.-S., Suh, C., Kim, Y.-K.
Clinical Lymphoma, Myeloma and Leukemia. 2012; 12(2): 118-126
[Pubmed]  [Google Scholar]
18 Perspectives in the elderly patient: Benefits and limits of bisphosphonates and denosumab
Santini, D., Fratto, M.E., Aapro, M.
Recent Results in Cancer Research. 2012; 192: 171-182
[Pubmed]  [Google Scholar]
19 Therapeutic approaches to myeloma bone disease: An evolving story
Longo, V., Brunetti, O., DæOronzo, S., Dammacco, F., Silvestris, F.
Cancer Treatment Reviews. 2012; 38(6): 787-797
[Pubmed]  [Google Scholar]
20 Sustained bone pain relief in breast cancer patients with metastatic bone disease treated with ibandronate: Final results of a large-scale noninterventional study
Diel, I.J., Schmidt, M., Maasberg, M., Bergner, R.
European journal of Clinical and Medical Oncology. 2011; 3(4): 17-23
[Pubmed]  [Google Scholar]
21 The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future
Pozzi, S., Raje, N.
Oncologist. 2011; 16(5): 651-662
[Pubmed]  [Google Scholar]
22 Multiple myeloma, severe hypercalcemia, acute renal failure and multiple organ failure due to calcinosis | [Mieloma múltiple, hipercalcemia severa, insuficiencia renal aguda y fallo multiorgánico por calcinosis]
Mateu, J.G.M., González, G.P.L., Vila, M.A.M., Rivera, M.U., Marqués, G.G., Tugores, A.C.
Nefrologia. 2011; 31(2): 233-234
[Pubmed]  [Google Scholar]
23 Assessment of the efficacy of pulse Ibandronate therapy in non-steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study
Sarkar, R.N., Bhattacharyya, K., Phaujdar, S., De, D.
Indian Journal of Rheumatology. 2011; 6(2): 55-60
[Pubmed]  [Google Scholar]
24 Assessment of the efficacy of pulse Ibandronate therapy in non-steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study
Rathindra Nath Sarkar,Kuntal Bhattacharyya,Sibaji Phaujdar,Dibyendu De
Indian Journal of Rheumatology. 2011; 6(2): 55
[Pubmed]  [Google Scholar] [DOI]
25 Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
Julie Rousseau,Virginie Escriou,François Lamoureux,Régis Brion,Julie Chesneau,Séverine Battaglia,Jérome Amiaud,Daniel Scherman,Dominique Heymann,Françoise Rédini,Valérie Trichet
Journal of Bone and Mineral Research. 2011; 26(10): 2452
[Pubmed]  [Google Scholar] [DOI]
26 Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: Review and Italian experience
Rossini, M. and Di Munno, O. and Gatti, D. and Giannini, S. and Minisola, S. and Varenna, M. and Adami, S.
Clinical and Experimental Rheumatology. 2011; 29(4): 728-735
[Pubmed]  [Google Scholar]
27 Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., (...), Trichet, V.
Journal of Bone and Mineral Research. 2011; 26(10): 2452-2462
[Pubmed]  [Google Scholar]

 

Read this article